Ligand Pharmaceuticals Incorporated (LGND)

Jul 2, 2025 - LGND was delisted (reason: merged into PTHS)
113.30
+0.74 (0.66%)
Inactive · Last trade price on Jul 2, 2025
33.53%
Market Cap 2.19B
Revenue (ttm) 181.49M
Net Income (ttm) -132.62M
Shares Out 19.29M
EPS (ttm) -7.11
PE Ratio n/a
Forward PE 109.86
Dividend n/a
Ex-Dividend Date n/a
Volume 106,499
Open 113.28
Previous Close 112.56
Day's Range 111.72 - 114.68
52-Week Range 81.74 - 129.90
Beta 0.71
Analysts Strong Buy
Price Target 144.71 (+27.72%)
Earnings Date Aug 5, 2025

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 18, 1992
Employees 68
Stock Exchange NASDAQ
Ticker Symbol LGND
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 8 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price target is $144.71, which is an increase of 27.72% from the latest price.

Price Target
$144.71
(27.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially la...

1 day ago - GlobeNewsWire

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 mill...

9 days ago - GlobeNewsWire

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company ...

9 days ago - GlobeNewsWire

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

I maintain my Buy rating on Ligand Pharmaceuticals due to its strong growth trajectory and diversified portfolio. Ligand offers investors exposure to dozens of therapies, reducing risk and increasing ...

16 days ago - Seeking Alpha

Ligand Announces 2025 Investor Day in New York City

JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 1...

4 weeks ago - GlobeNewsWire

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 20...

2 months ago - GlobeNewsWire

Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chie...

2 months ago - Seeking Alpha

Ligand Reports First Quarter 2025 Financial Results

First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Cr...

2 months ago - GlobeNewsWire

Ligand to Participate in May Investor Conferences

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...

2 months ago - GlobeNewsWire

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the ...

2 months ago - GlobeNewsWire

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug a...

3 months ago - GlobeNewsWire

Ligand to Participate in March Investor Conferences

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza w...

4 months ago - GlobeNewsWire

Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysi...

4 months ago - Seeking Alpha

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6...

4 months ago - GlobeNewsWire

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors...

Other symbols: XOMA
4 months ago - GlobeNewsWire

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

JUPITER, Fla.--(BUSINESS WIRE)--Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025.

5 months ago - Business Wire

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

JUPITER, Fla.--(BUSINESS WIRE)--Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

5 months ago - Business Wire

Looking Back On Ligand Pharmaceuticals

Today, I am circling back to Ligand Pharmaceuticals for the first time since late 2023. The stock has had a nice run in recent months and management has a solid game plan to grow revenues at north of ...

5 months ago - Seeking Alpha

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

6 months ago - Seeking Alpha

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Dav...

7 months ago - Business Wire

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, reinf...

8 months ago - Seeking Alpha

Ligand to Present at Stifel 2024 Healthcare Conference

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the...

8 months ago - Business Wire

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis...

8 months ago - Seeking Alpha

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance.

8 months ago - Business Wire

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m....

9 months ago - Business Wire